| Recruiting | HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequ NCT06595563 | Jules Bordet Institute | Phase 2 |
| Recruiting | SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Ce NCT07503717 | Royal College of Surgeons, Ireland | N/A |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Not Yet Recruiting | ARX788 in HER2-positive Metastatic Breast Cancer Patients NCT06663748 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast C NCT06551116 | Abramson Cancer Center at Penn Medicine | — |
| Recruiting | Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monothe NCT06298084 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 / Phase 2 |
| Recruiting | Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease NCT05800275 | UNICANCER | Phase 2 |
| Recruiting | Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical NCT06278870 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 |
| Recruiting | Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Brea NCT05959291 | University of Miami | N/A |
| Active Not Recruiting | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer NCT05650879 | Enliven Therapeutics | Phase 1 |
| Terminated | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-po NCT05583110 | Spanish Breast Cancer Research Group | Phase 2 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Active Not Recruiting | Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. NCT05230810 | Criterium, Inc. | Phase 1 / Phase 2 |
| Terminated | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors NCT05555251 | BioInvent International AB | Phase 1 / Phase 2 |
| Completed | Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer NCT06305702 | Liaoning Cancer Hospital & Institute | — |
| Unknown | Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer NCT06299852 | N.N. Petrov National Medical Research Center of Oncology | N/A |
| Terminated | Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer NCT04778982 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | — |
| Unknown | A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases NCT05042791 | Jiangxi Provincial Cancer Hospital | Phase 2 |
| Active Not Recruiting | ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) NCT04829604 | Ambrx, Inc. | Phase 2 |
| Active Not Recruiting | Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxici NCT05036252 | Memorial Sloan Kettering Cancer Center | — |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Unknown | ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases NCT05018702 | Fudan University | Phase 2 |
| Unknown | Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positi NCT05188495 | Peking University Cancer Hospital & Institute | — |
| Unknown | Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treat NCT04681287 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | Testing a New Imaging Agent to Identify Cancer NCT04692831 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC NCT04398108 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 |
| Completed | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors NCT04319757 | Acepodia Biotech, Inc. | Phase 1 |
| Unknown | Feasibility of a New Technology for Isolating Circulating Tumour Cells NCT03979339 | Centre Oscar Lambret | N/A |
| Unknown | A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast NCT03691051 | Henan Cancer Hospital | Phase 2 |
| Unknown | A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2 NCT04385563 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Active Not Recruiting | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC NCT03417544 | Nancy Lin, MD | Phase 2 |
| Unknown | Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer NCT03080805 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer NCT02973737 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2 NCT02605915 | Hoffmann-La Roche | Phase 1 |
| Unknown | A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Bre NCT02422199 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | The Myocet/Lapatinib Study. ICORG 10-03, V5 NCT01495884 | Cancer Trials Ireland | Phase 1 / Phase 2 |